II
CHRS icon

Inspire Investing’s Coherus Oncology CHRS Stock Holding History

Inspire Investing’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-73,887
Closed -$315K – 817
2023
Q2 		$315K Buy
73,887
+33,962
+85% +$200K 0.04% 461
2023
Q1 		$273K Buy
39,925
+9,482
+31% +$73.6K 0.03% 595
2022
Q4 		$241K Buy
30,443
+9,283
+44% +$71.4K 0.03% 358
2022
Q3 		$203K Sell
21,160
-8,095
-28% -$81.9K 0.03% 739
2022
Q2 		$212K Buy
29,255
+11,125
+61% +$96.7K 0.03% 491
2022
Q1 		$234K Buy
18,130
+2,936
+19% +$37.3K 0.03% 675
2021
Q4 		$242K Buy
15,194
+1,994
+15% +$34.9K 0.03% 767
2021
Q3 		$212K Buy
+13,200
New +$193K 0.03% 782
2020
Q3 		– Sell
-12,648
Closed -$226K – 453
2020
Q2 		$226K Sell
12,648
-189
-1% -$3.2K 0.08% 366
2020
Q1 		$208K Buy
+12,837
New +$237K 0.08% 406
2018
Q1 		– Sell
-6,431
Closed -$57K – 289
2017
Q4 		$57K Buy
+6,431
New +$68.8K 0.05% 454

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Inspire Investing's CHRS Position: Q3 2023 in Review

Inspire Investing sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 73,887 shares — an estimated $315K sold.

Inspire Investing first reported a position in CHRS in Q4 2017 and held it in 11 quarters. The position peaked at $315K in Q2 2023. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

  • Inspire Investing reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
  • Inspire Investing sold 73,887 Coherus Oncology shares in Q3 2023, an estimated $315K.
  • Inspire Investing first reported a position in Coherus Oncology in Q4 2017 and held it in 11 quarters.
  • Inspire Investing's Coherus Oncology position peaked at $315K in Q2 2023.
  • 169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Inspire Investing's 13F filing for Q3 2023, filed 26 Oct 2023.